Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00927810 · ClinicalTrials.gov registry record · Phase 2
Long Term Study of Canakinumab (ACZ885) in Patients With Gout
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 341
- Enrollment target
NCT00927810 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 341 participants.
The verdict
NCT00927810, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 341 participants
- Enrollment target
Study Summary
This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all the patients, irrespective whether they have an acute flare of gout or not. Patients will be treated on demand with canakinumab (ACZ885) in this extension study.
Interventions
- DRUG Canakinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2009-06-05 |
| Est. Completion | 2010-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00927810
The ClinicalTrials.gov registry entry for NCT00927810 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Canakinumab is the first listed.
NCT00927810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00927810 about?
NCT00927810 is a clinical study titled "Long Term Study of Canakinumab (ACZ885) in Patients With Gout". This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all the patients, irrespective whether they have an acute flare of gout or ...
What is the current status of trial NCT00927810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 341 participants. The study started on 2009-06-05. Estimated completion is 2010-08-04.
What interventions are being tested in trial NCT00927810?
The interventions under investigation include: Canakinumab (DRUG).
Who is sponsoring clinical trial NCT00927810?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.